Afrezza, world’s only rapid-acting, inhaled insulin for type 1 & type 2 diabetes patients & manufactured by MannKind, ...

Cipla to introduce Afrezza, an inhaled insulin for diabetes, offering convenience but not advised for lung-related concerns.

MannKind and Cipla announce CDSCO approves Afrezza inhalation powder in India: Our Bureau, Mumbai Thursday, December 12, 2024, 17:30 Hrs [IST] MannKind Corporation, a company focu ...

Mumbai: Cipla Limited has announced that it has obtained regulatory approval from Central Drugs Standard Control Organisation ...

Greaves Cotton board approved OFS of certain shares of arm Greaves Electric held by the company in the proposed IPO.

Cipla has secured exclusive rights to distribute and market Afrezza, an inhalable insulin, in India. Developed by MannKind, Afrezza offers a non-injectable alternative for managing type 1 and type 2 ...

Cipla receives approval to market Afrezza, a rapid-acting insulin inhaler, offering a needle-free solution for diabetes ...

Drug maker Cipla on Wednesday said it has received approval from the Central Drugs Standard Control Organisation for the ...

Taken at the beginning of a meal, the medication dissolves rapidly upon oral inhalation into the lungs and delivers insulin ...

Shares of MannKind Corporation climbed more than 2% in premarket trading Wednesday, on track to extend gains from the ...

Cipla secures CDSCO approval for Afrezza, a rapid-acting insulin delivered through an inhaler, offering a convenient solution ...

Cipla received approval from CDSCO to distribute and market Afrezza, an inhalable insulin, in India. Developed by MannKind, ...